ArticleBioengineered2021

Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC).

Wenguang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.